Business Description
Finch Therapeutics Group Inc
NAICS : 325412
SIC : 2834
200 Inner Belt Road, Suite 400, Somerville, MA, USA, 02143
Description
Finch Therapeutics Group Inc is a clinical-stage microbiome therapeutics company. It is leveraging Human-First Discovery platform to develop a novel class of orally administered biological drugs. It is developing novel therapeutics to deliver missing microbes and their clinically relevant biochemical functions to correct dysbiosis and the diseases that emerge from it. The lead product candidate is CP101 which delivers a complete microbiome and is being developed initially for the treatment of patients with recurrent Clostridioides difficile infection.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.9 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.35 | |||||
| Debt-to-EBITDA | -0.78 | |||||
| Piotroski F-Score | N/A/9 | |||||
| Altman Z-Score | -0.75 | |||||
| Beneish M-Score | -5.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.68 | |||||
| 9-Day RSI | 59.41 | |||||
| 14-Day RSI | 57.37 | |||||
| 6-1 Month Momentum % | -75.66 | |||||
| 12-1 Month Momentum % | -82.62 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.28 | |||||
| Quick Ratio | 7.28 | |||||
| Cash Ratio | 6.89 | |||||
| Days Sales Outstanding | 31.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History |
|---|
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -585.36 | |||||
| Net Margin % | -592.95 | |||||
| ROE % | -38.56 | |||||
| ROA % | -33.41 | |||||
| ROIC % | -82.2 | |||||
| ROC (Joel Greenblatt) % | -257.02 | |||||
| ROCE % | -34.98 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 7.96 | |||||
| PB Ratio | 0.63 | |||||
| Price-to-Tangible-Book | 1.13 | |||||
| EV-to-EBIT | -0.37 | |||||
| EV-to-Forward-EBIT | -0.99 | |||||
| EV-to-EBITDA | -0.41 | |||||
| EV-to-Forward-EBITDA | -1.17 | |||||
| EV-to-Revenue | 1.74 | |||||
| EV-to-Forward-Revenue | 12.43 | |||||
| EV-to-FCF | -0.98 | |||||
| Price-to-Net-Current-Asset-Value | 2.95 | |||||
| Price-to-Net-Cash | 3.47 | |||||
| Earnings Yield (Greenblatt) % | -266.46 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:FNCH
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 12.864 | ||
| EPS (TTM) ($) | -1.61 | ||
| Beta | 0 | ||
| Volatility % | 83.83 | ||
| 14-Day RSI | 57.37 | ||
| 14-Day ATR ($) | 0.222624 | ||
| 20-Day SMA ($) | 2.2815 | ||
| 12-1 Month Momentum % | -82.62 | ||
| 52-Week Range ($) | 1.7117 - 17.39 | ||
| Shares Outstanding (Mil) | 47.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Finch Therapeutics Group Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||